A gigantic advance in the fight against cancer they are getting doctors from Memorial Sloan Kettering, since they have found a drug that is allowing 100% remission of cancer in controlled patients.
referral is a concept is the period of time when the cancer is under control. The remission can be: “partial”, What does it mean that the cancer is responding well to treatment. “complete it What does it mean that the cancer has been missed by medical tests.
The therapy prevented participants with advanced rectal cancer from needing chemotherapy, radiation therapy or surgery to remove large parts of their colon.
The drug in question is an anti-PD-1 monoclonal antibody called dostarlimab. PD-1 is a protein that forms a complex with PD-L1 that is expressed outside of tumor cells. It acts as a “shield” for the immune system, telling immune cells not to attack the tumor and allowing it to grow out of control. It prevents T cells from attacking other cells that they shouldn’t. Cancer cells can co-opt PD-1, allowing them to go unnoticed by the immune system.
The phase 2 trial recruited 16 patients with mismatch repair-deficient colorectal cancer to take a six-month course that included nine cycles of dostarlimab. Of the 16, 12 had completed the course, while four were still in treatment.
Results? The 12 participants who had completed the course showed a 100 percent complete clinical response (the cancer was no longer detectable by a battery of tests). After a 12-month follow-up appointment, all 12 patients had no disease recurrence and all 16 patients were still alive. In addition, no serious adverse events were reported, although 12 patients experienced an adverse event of some degree, most commonly a rash or fatigue.
“I think this is the first time this has happened in the history of cancer,” he told New York Times Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Luis Diaz Jr., lead author of a new item which reports the results.